• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?单侧黄斑新生血管 3 型患者是否需要 AREDS 补充剂来减缓向年龄相关性黄斑变性的进展？
Eye (Lond). 2023 Jun;37(9):1751-1753. doi: 10.1038/s41433-022-02249-2. Epub 2022 Sep 29.
2
Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.英国年龄相关性黄斑变性研究补充剂的成本效益：联合试验和真实世界结局数据。
Br J Ophthalmol. 2018 Apr;102(4):465-472. doi: 10.1136/bjophthalmol-2017-310939. Epub 2017 Aug 23.
3
Geographic Atrophy and micronutritional supplements: A complex relationship.地理性萎缩与微量营养素补充剂：一种复杂的关系。
J Fr Ophtalmol. 2019 Dec;42(10):1111-1115. doi: 10.1016/j.jfo.2019.07.003. Epub 2019 Nov 10.
4
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.叶黄素+玉米黄质和欧米伽-3 脂肪酸治疗年龄相关性黄斑变性：年龄相关性眼病研究 2（AREDS2）随机临床试验。
JAMA. 2013 May 15;309(19):2005-15. doi: 10.1001/jama.2013.4997.
5
Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial.应用于年龄相关性黄斑变性预防试验并发症参与者的年龄相关性眼病研究9级严重程度量表的描述。
Arch Ophthalmol. 2009 Sep;127(9):1147-51. doi: 10.1001/archophthalmol.2009.189.
6
Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19.年龄相关性眼病研究（AREDS）中晚期年龄相关性黄斑变性发病率的风险因素。AREDS报告第19号。
Ophthalmology. 2005 Apr;112(4):533-9. doi: 10.1016/j.ophtha.2004.10.047.
7
Prevention and treatment of age-related macular degeneration: an update for pharmacists.年龄相关性黄斑变性的预防与治疗：药剂师须知的最新进展
Consult Pharm. 2013 Nov;28(11):723-37. doi: 10.4140/TCP.n.2013.723.
8
Evidence-based vitamin supplements for age-related macular degeneration: an analysis of available products.针对年龄相关性黄斑变性的循证维生素补充剂：对现有产品的分析。
Clin Exp Optom. 2022 Nov;105(8):836-841. doi: 10.1080/08164622.2021.1989264. Epub 2021 Nov 15.
9
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11.年龄相关性眼病研究结果对公共卫生的潜在影响：年龄相关性眼病研究（AREDS）报告第11号
Arch Ophthalmol. 2003 Nov;121(11):1621-4. doi: 10.1001/archopht.121.11.1621.
10
Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity: AREDS Report 41.AMD 严重程度量表 2 年进展与晚期年龄相关性黄斑变性或视力丧失的相关性：AREDS 报告 41。
JAMA Ophthalmol. 2020 Jun 1;138(6):610-617. doi: 10.1001/jamaophthalmol.2020.0824.

引用本文的文献

1
Short-Term Morphological and Quantitative Changes in Non-Exudative Macular Neovascularization Using Spectral-Domain OCT and OCT Angiography: A Pilot Study.使用光谱域光学相干断层扫描（SD-OCT）和光学相干断层扫描血管造影（OCTA）对非渗出性黄斑新生血管进行的短期形态学和定量变化：一项初步研究
J Clin Med. 2025 May 22;14(11):3622. doi: 10.3390/jcm14113622.
2
Review of type 3 macular neovascularization in age-related macular degeneration: no DRAMA (Deep Retinal Age-related Microvascular Anomalies).年龄相关性黄斑变性中3型黄斑新生血管的综述：无DRAMA（深部视网膜年龄相关性微血管异常）
Eye (Lond). 2025 Apr;39(5):870-882. doi: 10.1038/s41433-024-03343-3. Epub 2024 Oct 11.
3
The potential key role of choroidal non-perfusion and rod degeneration in the pathogenesis of macular neovascularization type 3.脉络膜无灌注和杆状细胞变性在 3 型黄斑新生血管发病机制中的潜在关键作用。
Eye (Lond). 2024 Jul;38(10):1836-1839. doi: 10.1038/s41433-024-03034-z. Epub 2024 Mar 18.
4
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration.当前对与年龄相关性黄斑变性相关的 3 型黄斑新生血管的认识。
Ophthalmologica. 2024;247(2):73-84. doi: 10.1159/000536278. Epub 2024 Jan 24.

本文引用的文献

1
THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3: Multimodal Imaging of Fellow Eyes over 24 months.RAP 研究，报告 5：重新发现黄斑新生血管 3 型：24 个月以上对侧眼的多模态成像。
Retina. 2022 Mar 1;42(3):485-493. doi: 10.1097/IAE.0000000000003330.
2
The RAP study, report 4: morphological and topographical characteristics of multifocal macular neovascularization type 3.RAP 研究，报告 4：多灶性黄斑新生血管病变 3 型的形态学和解剖学特征。
Graefes Arch Clin Exp Ophthalmol. 2022 Jan;260(1):141-147. doi: 10.1007/s00417-021-05332-8. Epub 2021 Aug 26.
3
The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3.RAP 研究，报告 3：3 型黄斑新生血管患者黄斑区变色。
Acta Ophthalmol. 2022 Feb;100(1):e270-e277. doi: 10.1111/aos.14866. Epub 2021 Apr 5.
4
RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3.RAP 研究，报告 1：新型 III 型黄斑新生血管亚型，脉络膜睫状 MNV3。
Br J Ophthalmol. 2021 Jan;105(1):113-117. doi: 10.1136/bjophthalmol-2019-315311. Epub 2020 Mar 11.
5
CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus.监测新生血管性年龄相关性黄斑变性对侧眼的当前概念和模式：专家小组共识。
Retina. 2020 Apr;40(4):599-611. doi: 10.1097/IAE.0000000000002768.
6
THE RAP STUDY, REPORT TWO: The Regional Distribution of Macular Neovascularization Type 3, a Novel Insight Into Its Etiology.RAP 研究，报告二：3 型黄斑新生血管的区域性分布，对其病因的新认识。
Retina. 2020 Dec;40(12):2255-2262. doi: 10.1097/IAE.0000000000002774.
7
INFLUENCE OF FELLOW-EYE EXAMINATION INTERVAL ON VISUAL ACUITY AT FELLOW-EYE NEOVASCULARIZATION IN UNILATERAL TYPE 3 NEOVASCULARIZATION.单眼型 3 型新生血管中对侧眼检查间隔对视力的影响。
Retina. 2020 Jul;40(7):1255-1261. doi: 10.1097/IAE.0000000000002603.
8
CHARACTERISTICS OF TYPE 3 NEOVASCULARIZATION LESIONS: Focus on the Incidence of Multifocal Lesions and the Distribution of Lesion Location.3 型新生血管病变的特征：重点关注多发病灶的发生率和病变位置分布。
Retina. 2020 Jun;40(6):1124-1131. doi: 10.1097/IAE.0000000000002489.
9
REDUCED CHORIOCAPILLARIS FLOW IN EYES WITH TYPE 3 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION.伴有 3 型新生血管和年龄相关性黄斑变性的眼脉络膜血流减少。
Retina. 2018 Oct;38(10):1968-1976. doi: 10.1097/IAE.0000000000002198.
10
Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).年龄相关性黄斑变性治疗试验（CATT）中视网膜血管瘤样增生患者的治疗结果
Ophthalmology. 2016 Mar;123(3):609-16. doi: 10.1016/j.ophtha.2015.10.034. Epub 2015 Dec 8.

单侧黄斑新生血管 3 型患者是否需要 AREDS 补充剂来减缓向年龄相关性黄斑变性的进展？

Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?

机构信息

Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.

出版信息

Eye (Lond). 2023 Jun;37(9):1751-1753. doi: 10.1038/s41433-022-02249-2. Epub 2022 Sep 29.

DOI:10.1038/s41433-022-02249-2
PMID:36175488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10275938/
Abstract

Given the wide spectrum of unique characteristics of macular neovascularization type 3 (MNV3) compared with types 1 and 2, we suggest regrading the colour photography assessment of the AREDS study to verify the impact of AREDS supplements on eyes with MNV3.

摘要

鉴于与类型 1 和 2 相比，黄斑新生血管 3 型（MNV3）具有广泛的独特特征，我们建议重新评估 AREDS 研究的彩色摄影评估，以验证 AREDS 补充剂对 MNV3 眼的影响。